Through this key area of work, we want to:
We’re working across several areas to achieve our goals.
Vaccines are a vital tool for fighting epidemics, but developing a vaccine from scratch typically takes more than 10 years. We’re working to support the development of vaccines against known diseases, and of new technology to accelerate vaccine development when new threats appear.
Vaccines work best when they are developed specifically for the populations most at risk. An effective way to do this is through human infection studies, which involve testing the vaccines on volunteers from relevant communities.
Vaccines can help prevent infections which are resistant to antibiotics, and diseases which can lead to unnecessary prescription of antibiotics. But they’re not used enough as a tool to tackle drug-resistant infections.
For this, we:
For advances in vaccine science to benefit more people, more quickly, implementation and evidence need to be more closely linked.
One example where this link could be stronger is between cholera control and research. Cholera, often thought of as a disease of history, still causes an estimated 2.9 million cases and 95,000 deaths every year.
Countries, particularly low- and middle-income countries with high burdens of infectious disease, need to be able to develop independent policies on immunisation that are based on research evidence, local disease burden and cost-effectiveness. To do this, they need access to relevant evidence, clear decision-making pathways, and technical skills and expertise.
We’re working to identify, fund, share and apply relevant research so that decisions can be based on better information. This includes:
Vaccines already save millions of lives, but they could be saving many millions more. This can only happen with the support of global policy makers.
A vaccine for COVID-19 which uses cutting-edge RNA technology has entered phase 1 clinical trials. If successful, it could revolutionise the future of vaccine development.